AI Article Synopsis
- * A study analyzed 7 patients with liver-dominant mCRPC treated with TARE, revealing median overall survival rates of 27.2, 32.1, and 108.1 months from different starting points.
- * The study found no serious side effects and concluded that TARE appears to be a safe and effective treatment option for this specific group of patients.
Article Abstract
Transarterial radioembolization (TARE) with yttrium-90 glass microspheres is widely used to treat primary and secondary malignancies in the liver. However, the safety and efficacy of TARE in patients with liver-dominant metastatic castration-resistant prostate cancer (mCRPC) is unknown. A proof-of-concept, retrospective analysis of 7 consecutive patients with liver-dominant mCRPC who were treated with TARE was performed. The median overall survival was 27.2, 32.1, and 108.1 months from the time of TARE, the diagnosis of liver metastases, and initial cancer diagnosis, respectively. The median liver progression-free survival was 7.3 months. No grade 3 or higher adverse effects were noted. TARE was found to be a safe and effective tool for treating patients with liver-dominant mCRPC in this limited cohort.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jvir.2022.05.023 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!